Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT05205330 Recruiting - Solid Tumor Clinical Trials

A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients

Start date: November 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase Ib/IIa study has been designed according to a 3+3 dose escalation/dose expansion design. A dose expansion will be conducted at both the intermediate and high dose levels, if tolerated, with the purpose of generating additional and more robust safety and preliminary efficacy data. No control arm was included, as the target patient population of this study consists of patients in whom the overall survival is less than 6 months and treatment options are very limited and often poorly tolerated, making unlikely that the study results can be significantly biased.

NCT ID: NCT05204862 Recruiting - Solid Tumor Clinical Trials

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Start date: December 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2 dose (RP2D) of TU2218 and the main purpose of Phase 2 is to evaluate the antitumor activity of TU2218 at RP2D.

NCT ID: NCT05199519 Recruiting - Solid Tumor Clinical Trials

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

Start date: December 13, 2021
Phase: Phase 1
Study type: Interventional

A phase Ia study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of IBI345 in patients with CLDN18.2 positive solid tumors

NCT ID: NCT05199272 Recruiting - Solid Tumor Clinical Trials

A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Start date: December 29, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human open-label Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

NCT ID: NCT05198752 Not yet recruiting - Solid Tumor Clinical Trials

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Start date: January 12, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine´╝îin patients with advanced malignant solid tumours.

NCT ID: NCT05196360 Recruiting - Solid Tumor Clinical Trials

MAX-10181 in Patients With Advanced Solid Tumor

PD-L1
Start date: August 11, 2021
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

NCT ID: NCT05192174 Not yet recruiting - Solid Tumor Clinical Trials

Study of NIB101 in Participants With Advanced Solid Tumors

Start date: January 25, 2022
Phase: Phase 1
Study type: Interventional

NIB101-01 study is an open-label, non-randomized Phase 1 study in participants with GM2 positive advanced solid tumor, who failed to available standard of cares to evaluate the safety and tolerability of NIB101.

NCT ID: NCT05190263 Recruiting - Solid Tumor Clinical Trials

Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma

QA Anemia
Start date: October 25, 2021
Phase:
Study type: Observational

The aim of the study is to analyze the implementation of the 2018 updated ESMO Guideline in patients with tumor diseases as well as the corre-sponding recommendations of the Onkopedia Guideline and the S3 Guide-line Supportive Therapy in routine clinical practice in Germany. To this end, a nationwide, representative, retrospective patient documen-tation will be conducted to observe the current practice of anemia man-agement in hospitals and among office-based physicians.

NCT ID: NCT05181865 Not yet recruiting - Gastric Cancer Clinical Trials

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Start date: February 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced cancer.

NCT ID: NCT05176509 Not yet recruiting - Solid Tumor Clinical Trials

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors

Start date: January 2022
Phase: Phase 1
Study type: Interventional

A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors